GEFITINIB相关论文
研究背景:CMTM,原名CKLFSF,是北京大学免疫学系于2003年首次报道的基因家族。在人类,该家族包括9个基因,即:CKLF和CMTM1-8（原名CKLF......
PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by
Recent studies show that intracellular accumulation of cholesterol leads to acquired resistance to gefitinib in non-smal......
1例67岁男性患者因“肺癌，表皮生长因子受体（epidermal growth factor receptor，EGFR）基因21外显子突变”服用吉非替尼每天250 mg，3个月......
Objective:To evaluate the potential pharmacokinetic interactions of the anticancer agent gefitinib (Iressa(R)) and the o......
Objective:To evaluate the effect of Fuzheng Kang\'ai Formula (扶正抗癌方,FZKA) plus gefitinib in patients with advance......
Functionalized PLGA-PEG nanoparticles conjugated with aptamer and gadolinium for MRI imgaing and dru
Magnetic resonance imaging(MRI)is one of the most powerful clinical techniques in cancer diagnosis.Much attention has be......
目的 We previously reported that GOLPH3 promotes glioma progression by inhibiting EGFR endocytosis and degradation,leadi......
...
Objective As first line therapy,EGFR tyrosine kinase inhibitors(TKIs),have displayed dramatic clinical response and long......
Gefitinib with or without transarterial infusion chemotherapy(cisplatin)for large non-small cell lun
Objective Purpose: To retrospectively investigate the safety and benefit of gefitinib plus transarterial infusion(TAI)th......
目的 we design the study aiming at detecting the pharmacokinetic difference among gefitinib,icotinib,erlotinib,and OSI-4......
Malignant pleural effusion deterioration does not indicate resistance to Gefitinib in the early trea
...
Combination of chemotherapy and gefitinib as first-line treatment of patients with advanced lung ade
目的 To explore the optimal treatment strategy for patients who harbored a sensitive EGFR mutation.We did a head-to-head......
MetforminenhancescytotoxicityinducedbygefitinibinH1975cellsviareversingEMTandsuppressin
目的 AlthoughtheEGFRtyrosinekinaseinhibitors(EGFR-TKI)haveshownstrikingeffectsagainstEGFRmutantlungcancer,butpatientswit......
Superior Outcomes of 1st line EGFR TKI in Next-generation Sequencing Identified Uncommon EGFR exon 1
Objective First line EGFR-TKI showed promising efficacy on EGFR mutant advanced nonsmall cell lung cancers(NSCLC)....
Preparation and evaluation of gefitinib-loaded human serum albumin nanoparticles for therapy of non-
...
A single center, single arm and Phase Ⅱ clinical trail: the study of efficacy and safety of pulsatil
Objective: To observe the efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanc......
Enoxaparin sensitizes human non-small-cell lung carcinomasto gefitinib by inhibiting DOCK1 expressio
Gefitinib is widely used for the treatment of lung cancer in patients with sensitizing epidermal growth factor receptor ......
Blockade of methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer c
Background: The sensitivity of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) ha......
Background: Gefitinib binds to the ATP-binding site of EGFR tyrosine kinases to interrupt the abnormally activated anti-......
Objective: To evaluate the effect of"Fuzheng Kangai (FZKA)" decoction plus Gefitinib on patients with non-small cell l......
非小细胞肺癌(NSCLC)是一种严重威胁人类生命健康的疾病，药物Gefitinib 可以抑制EGFR 下游与肿瘤相关的增殖、逃逸与血管新生信号通......
Chemotherapy with or without gefitinib in patients with advanced non-small-cell lung cancer: a meta-
...
目的观察对常规剂量获得性耐药的肺腺癌患者接受更高每日剂量吉非替尼治疗的疗效与安全性。方法收集加14年1月至2015年12月对吉非......
目的分析一线应用埃克替尼和吉非替尼治疗晚期表皮生长因子受体(EGFR)阳性肺腺癌患者的疗效。方法回顾性分析120例口服埃克替尼或......
ＡｓｔｒａＺｅｎｅｃａ公司说它将继续关注ｇｅｆｉｔｉｎｉｂ(Ｉｒｅｓ ｓａ)复合化疗对非小细胞肺癌的疗效 ,尽管ｇｅｆｉｔｉｎｉｂ复合治疗非小细胞肺癌临床试验 (ＩＮＴＡＣＴ)已经失败 ,试验报告已在 2 0 0 2年 1......
目的：通过描述、分析在使用吉非替尼或厄罗替尼过程中出现听力减退的5例晚期非小细胞肺癌患者的临床特征及听力损害表现，揭示两药与......
目的观察放疗联合吉非替尼治疗老年人中晚期非小细胞肺癌的近期及远期疗效。方法选取临沂市第三人民医院2012年10月至2015年10月确......
目的观察吉非替尼联合羟基喜树碱心包灌注用于晚期非小细胞肺癌(NSCLC)伴心包积液的临床效果。方法选取胶州市人民医院2016年1月至......
目的探讨吉非替尼联合胸部同步放疗在治疗表皮生长因子受体(EGFR)基因突变敏感型局部晚期非鳞肺癌患者中的临床获益及安全性。方法......
目的探讨顺铂与吉西他滨联合化学治疗对中晚期非小细胞肺癌患者的影响。方法选取2014年3月至2015年3月山东省滨州市中心医院肿瘤科......
Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib
AIM: To analyze the biological effects of prolonged in vitro exposure of HT-29 and LoVo colon cancer cell lines to gefit......
1例70岁男性晚期肺癌患者口服吉非替尼250 mg、1次/d。此前患者因瓣膜关闭不全行主动脉瓣置换术及冠状动脉搭桥术，术后长期规范服用......
A Phase Ⅱ Trial of Gefitinib as Maintenance Therapy after First-Line Chemotherapy for Advanced Non-S
Objective:To investigate the efficacy and safety of gefitinib as maintenance therapy for advanced non-small cell lung ca......
背景:全世界的统计数据表明,肺癌仍然是导致癌症发生率和癌症死亡率较高的主要原因(占癌症死亡总数的18.4%)和最常被诊断出的癌症......
目的 探讨吉非替尼对2型糖尿病鼠胰岛素敏感性的影响及其相关机制.方法 高糖高脂饲料喂养大鼠1个月后腹腔注射链脲霉素制成2型糖尿......
目的探讨受体酪氨酸激酶抑制剂Gefitinib在体内外对激素非依赖前列腺癌(HIPC)的抑制作用及其效应机制。方法不同浓度的Gefitinib处......
20 0 2年 8月ＡｓｔｒａＺｅｎｅｃａ公司宣布 ,其新研制的抗癌药 ｇｅｆｉｔｉｎｉｂ(Ｉｒｅｓｓａ ,ＺＤ1839) ,一种表皮生长因子受体 (ＥＧＦＲ)酪氨酸激酶抑制剂 ,在与铂类化疗药伍用治疗非小细胞......
20 0 3年 5月 5日 ,阿斯利康宣布Iressa(gefitinib)被FDA批准作为非小细胞肺癌的三线治疗药物 ,2 5 0mg片剂 ,qd。本品为表皮生长......
目的:探讨吉非替尼对血管平滑肌细胞(VSMC)及内皮细胞(EC)增殖的不同作用,及其与表皮生长受体因子(EGFR)磷酸化的关系.方法:分别用......
近几年,表皮生长因子受体(epidermal growth factor receptor,EGFR)是肿瘤学药物研发的一个重要靶点。EGFR的小分子抑制剂(tyrosin......
目的:鉴定益气养阴解毒抗突变复方的抗突变功效,回顾性分析该方同步配合表皮生长因争受体酪氨酸激酶抑制剂吉非替尼治疗表皮生长因......
目的探讨miR-374a和miR-548调控非小细胞肺癌对吉非替尼耐药的机制。方法 1qRT-PCR检测转染载体miR-Zip-347a或p-miR-548b的HCC827......
目的:研究Gefitinib对人胶质瘤U251细胞的生长抑制作用及相关机制。方法:用四甲基偶氮唑盐(MTT)比色法检测不同浓度Gefitinib对U25......
药物动力学研究表明胃酸抑制药(gastric acid suppression,AS)可以减少吉非替尼的暴露.然而,这种药物-药物相互作用的临床意义尚未......
目的:探讨吉非替尼诱发的严重间质性肺病(interstitial lung disease,ILD)的发病机制、诊断与治疗。方法:对1例吉非替尼导致的ILD......
